Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Clinical Trials Related to Olaparib
Related studies linked through entity extraction aliases.
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
- Status
- WITHDRAWN
- Phase
- PHASE2
Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation
- Status
- UNKNOWN
- Phase
- PHASE2
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.
- Status
- RECRUITING
- Phase
- PHASE3
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
SMMART Adaptive Clinical Treatment (ACT) Trial
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy
- Status
- RECRUITING
- Phase
- PHASE2
Chemo-free BRCA-targeted Neoadjuvant Strategy
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).
- Status
- UNKNOWN
- Phase
- PHASE2
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
- Status
- UNKNOWN
- Phase
- PHASE2
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
- Status
- COMPLETED
- Phase
- PHASE2
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2